2023
Mutation-specific costs of advanced non-small cell lung cancer treatment.
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Mutation-specific costs of advanced non-small cell lung cancer treatment. JCO Oncology Practice 2023, 19: 14-14. DOI: 10.1200/op.2023.19.11_suppl.14.Peer-Reviewed Original ResearchAdvanced non-small cell lung cancerNon-small cell lung cancerMean medication costsActionable gene alterationsMedication costsFirst-year costsReference groupAdvanced non-small cell lung cancer (NSCLC) treatmentNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentGene alterationsBiomarker resultsFlatiron Health databasePD-L1 resultsTherapy prolongs survivalRetrospective cohort studyCell lung cancerBiomarker test resultsLung cancer treatmentCost-effectiveness analysisCohort studyNovel immunotherapiesOverall cohortProlong survivalTreatment options
2015
“The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment.
Presley C, Soulos P, Yu J, Gross C. “The burden upon me”: The complexity of healthcare utilization among Medicare patients undergoing curative lung cancer treatment. Journal Of Clinical Oncology 2015, 33: 7533-7533. DOI: 10.1200/jco.2015.33.15_suppl.7533.Peer-Reviewed Original Research